Abstract

We examined the effects of atomoxetine in Latino (L) vs. Caucasian (C) pediatric outpatients (6-18 years of age) during the first 10-11 weeks of treatment in two multi-center, open-label trials. Mean modal doses were not significantly different in L’s (1.22 mg/kg/d; n=108) vs. C’s (1.27 mg/kg/d; n= 1090; p=0.22). Both groups showed significant improvement in ADHDRS-IV-P:I, CPRS-R:S, and CGI-ADHD-S scores without significant between group differences. The only significant difference was a greater decrease in the ADHDRS-IV-P:I hyperactive/impulsive subscale during weeks 8-11 for L’s vs. C’s, but not in the CPRS-R:S hyperactivity subscale. C’s reported significantly more abdominal and throat pain, L’s reported more decreased appetite and dizziness. No differences in other common adverse events were found. No suicidal behavior was reported in either group. We found that Latino and Caucasian children with ADHD exhibit a similar pattern of efficacy and tolerability with atomoxetine.